Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28:109–118.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Debacker AJ, Voutila J, Catley M, Blakey D, Habib N. Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol Ther. 2020;28:1759–1771.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu X, Liu S, Liu D, Li X, Wang H, Han X. Global and Chinese trends in oligonucleotide drug clinical development: a comparative analysis. Pharmacol Res. 2024;210:107487.

Zhang Y, Chen H, Hong L, Wang H, Li B, Zhang M, et al. Inclisiran: a new generation of lipid-lowering siRNA therapeutic. Front Pharm. 2023;14:1260921.

Article  CAS  Google Scholar 

Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507–1519.

Article  CAS  PubMed  Google Scholar 

Qin Z-X, Zuo L, Zeng Z, Ma R, Xie W, Zhu X, et al. GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases. Expert Opin Drug Deliv. 2025;22:455–469.

Article  CAS  PubMed  Google Scholar 

Kaffe E, Roulis M, Zhao J, Qu R, Sefik E, Mirza H, et al. Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions. Cell. 2023;186:3793–3809.e26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malecova B, Burke RS, Cochran M, Hood MD, Johns R, Kovach PR, et al. Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs). Nucleic Acids Res. 2023;51:5901–5910.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23:709–17.

Article  CAS  PubMed  Google Scholar 

Cuellar TL, Barnes D, Nelson C, Tanguay J, Yu SF, Wen X, et al. Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res. 2015;43:1189–203.

Article  CAS  PubMed  Google Scholar 

Janas MM, Schlegel MK, Harbison CE, Yilmaz VO, Jiang Y, Parmar R, et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat Commun. 2018;9:723.

Article  PubMed  PubMed Central  Google Scholar 

Zhang C, Dai P, Vinogradov AA, Gates ZP, Pentelute BL. Site-Selective Cysteine–Cyclooctyne Conjugation. Angew Chem Int Ed. 2018;57:6459–6463.

Article  CAS  Google Scholar 

Song X, Wang X, Ma Y, Liang Z, Yang Z, Cao H. Site-Specific Modification Using the 2′-Methoxyethyl Group Improves the Specificity and Activity of siRNAs. Mol Ther - Nucleic Acids. 2017;9:242–250.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geall AJ, Doppalapudi VR, Chu DS-H, Cochran MC, Hood M, Darimont BD, et al. Compositions and methods of treating muscle atrophy and myotonic dystrophy. PubChem Patent Summary for US-10881743-B2.

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19:673–694.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meng Q, Yang M, Xing F, Xie Z, Hao Y, Jiang P, et al. Antibody-oligonucleotide conjugates in cancer therapy: potential and promise. Crit Rev Oncol/Hematol. 2025;215:104858.

Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, et al. Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharm Sin B. 2021;11:3889–3907.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rennick JJ, Johnston APR, Parton RG. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat Nanotechnol. 2021;16:266–276.

Article  CAS  PubMed  Google Scholar 

Candelaria PV, Leoh LS, Penichet ML, Daniels-Wells TR. Antibodies targeting the transferrin receptor 1 (TfR1) as direct anti-cancer agents. Front Immunol. 2021;12:607692.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aisen P. Transferrin receptor 1. Int J Biochem Cell Biol. 2004;36:2137–2143.

Article  CAS  PubMed  Google Scholar 

Etxaniz U, Diaz M, Bhardwaj R, Tyaglo O, Lemoine K, Missinato MA, et al. Antibody-oligonucleotide conjugates (AOCs) demonstrate potent and durable exon skipping and dystrophin restoration in a mouse model of duchenne muscular dystrophy (S23.003). Neurology. 2022;98:1761.

Article  Google Scholar 

Girgenrath M, Estrella N, Kumar A, Li J, Hicks A, Brennan C, et al. P20 Endosomal Escape Vehicles (EEV™) - Oligonucleotides conjugates produce exon skipping and dystrophin production in preclinical models of Duchenne muscular dystrophy. Neuromuscul Disord. 2023;33:S102.

Article  Google Scholar 

Alam R, Alvarado A, Andrews FH, Babb NA, Balasubramaniam D, Chauvigne-Hines L, et al. Transferrin receptor binding proteins and conjugates. Publication Number WO/2024/036096.

Lee HN, Jeong MS, Jang SB. Molecular characteristics of amyloid precursor protein (APP) and its effects in cancer. Int J Mol Sci. 2021;22:4999.

Gordon RE, Nemeth JF, Singh S, Lingham RB, Grewal IS. Harnessing SLE autoantibodies for intracellular delivery of biologic therapeutics. Trends Biotechnol. 2021;39:298–310.

Article  CAS  PubMed  Google Scholar 

Rattray Z, Deng G, Zhang S, Shirali A, May CK, Chen X, et al. ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody. JCI Insight. 2021;6:e145875.

Naes SM, Ab-Rahim S, Mazlan M, Abdul Rahman A, Zhang DM. Equilibrative nucleoside transporter 2: properties and physiological roles. BioMed Res Int. 2020;2020:5197626.

Anderson CM, Baldwin SA, Young JD, Cass CE, Parkinson FE. Distribution of mRNA encoding a nitrobenzylthioinosine-insensitive nucleoside transporter (ENT2) in rat brain. Brain Res Mol Brain Res. 1999;70:293–7.

Article  CAS  PubMed  Google Scholar 

Manso T, Sanou G, Nousias C, Maalem I, Boutin F, Giudicelli V, et al. Identification of engineered IMGT Fc variants in IMGT/mAb-DB, a database of therapeutic antibodies and fusion proteins. MAbs. 2025;17:2594260.

Article  PubMed  PubMed Central  Google Scholar 

Rackear M, Quijano E, Ianniello Z, Colón-Ríos DA, Krysztofiak A, Abdullah R, et al. Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition. Oncotarget. 2024;15:699–713.

Article  PubMed  PubMed Central  Google Scholar 

Chen CF, Hsu EC, Lin KT, Tu PH, Chang HW, Lin CH, et al. Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma. Hepatology. 2010;52:1690–701.

Article  CAS  PubMed  Google Scholar 

Farré X, Guillén-Gómez E, Sánchez L, Hardisson D, Plaza Y, Lloberas J, et al. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer. 2004;112:959–66.

Article  PubMed  Google Scholar 

Tufail M, Jiang C-H, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduction Targeted Therapy. 2025;10:227.

Lanza F, Maffini E, Rondoni M, Massari E, Faini AC, Malavasi F. CD22 expression in B-cell acute lymphoblastic leukemia: biological significance and implications for inotuzumab therapy in adults. Cancers. 2020;12:303.

Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C. A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia. Int J Mol Sci. 2021;22:2150.

Duan S, Paulson JC. Siglecs as immune cell checkpoints in disease. Annu Rev Immunol. 2020;38:365–395.

Article  CAS  PubMed  Google Scholar 

Uy N, Nadeau Nguyen M, Stahl M, Zeidan A. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. J Blood Med. 2018;9:67–74.

Article  Google Scholar 

Kwong LS, Brown MH, Barclay AN, Hatherley D. Signal-regulatory protein α from the NOD mouse binds human CD47 with an exceptionally high affinity – implications for engraftment of human cells. Immunology. 2014;143:61–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eladl E, Tremblay-LeMay R, Rastgoo N, Musani R, Chen W, Liu A, et al. Role of CD47 in hematological malignancies. J Hematol Oncol. 2020;13:96.

Article  PubMed  PubMed Central